360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

BAVARIAN NORDIC A/S

Type: Company

Name: BAVARIAN NORDIC A/S (Bavarian Nordic A S)

Fact Sheet: Fact Sheet for Bavarian Nordic A/S

First reported May 16 2013 - Updated May 17 2013 - 1 reports

Bavarian Nordic A/S Maintains FY 2013 Financial Guidance

Bavarian Nordic A/S announced that the Company's fiscal year 2013 financial guidance remains unchanged. The Company continues to expect fiscal year revenues in the level of DKK 1,100 million and a break-even result before tax. According to I/B/E/S Estimates, ... [Published Reuters - May 16 2013]

Entities: BAVARIAN NORDIC A/S, Fiscal Year, B E S Ltd

First reported May 15 2013 - Updated May 15 2013 - 1 reports

New Report Examines Therapeutic Cancer Vaccine Market

“Therapeutic Cancer Vaccines – Current Status and Future Promise” is the title of a new report by Fran Brown, Senior Advisor at healthcare corporate finance and strategy specialist, Results Healthcare. The report begins by looking at the approval of ... [Published Pharma-Mag - May 15 2013]

Entities: cancer vaccine, Cancer, Market, Vaccine

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Bavarian Nordic to Host First Quarter 2013 Results Conference Call

- Bavarian Nordic A/S (OMX:$ BAVA) will announce its 2013 first quarterly results on Thursday, May 16, 2013.The company will host a conference call at 2:00 pm CET (8:00 am EDT) on the same day. President and CEO, Anders Hedegaard will present the interim ... [Published ACN Newswire - May 08 2013]

Entities: BAVARIAN NORDIC A/S, Vaccine, Phase III, Infectious Diseases

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Bavarian Nordic A/S - Articles of Association

Bavarian Nordic - Articles of AssociationThis announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.The owner of this announcement warrants that:(i) the releases contained herein are protected by copyright and other applicable ... [Published Reuters - May 02 2013]

Entities: BAVARIAN NORDIC A/S, warrants

First reported Apr 29 2013 - Updated Apr 29 2013 - 1 reports

Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 Trial

(GLOBE NEWSWIRE) -- Bavarian Nordic A/S (OMX: BAVA) today announced that the Company plans to conduct an interim analysis of the on-going PROSPECT Phase 3 trial of PROSTVAC(r) in prostate cancer patients with metastatic disease. The updated statistical ... [Published Asian Hospital & Healthcare Management - Apr 29 2013]

Entities: BAVARIAN NORDIC A/S, Phase III, Prostate Cancer, Patient

First reported Apr 24 2013 - Updated Apr 24 2013 - 1 reports

Bavarian Nordic A/S - Major Shareholder Announcement

- Bavarian Nordic A/S (OMX: BAVA) has received information from OrbiMed Advisors LLC that the company has decreased its ownership in Bavarian Nordic from 5.35 % to 4.53 % of the shares and voting rights in Bavarian Nordic.Asger AamundChairman of the ... [Published Reuters - Apr 24 2013]

Entities: BAVARIAN NORDIC A/S, Vaccine, Infectious Diseases, Anders Hedegaard, OrbiMed Advisors LLC

First reported Apr 17 2013 - Updated Apr 18 2013 - 1 reports

Bavarian Nordic A/S - Orientering om forløb af ordinær generalforsamling den 17. april 2013

KVISTGÅRD, Danmark - 17. april 2013 - Bavarian Nordic A/S (OMX: BAVA) har i dag,onsdag den 17. april 2013, afholdt ordinær generalforsamling med følgenderesultater:* Bestyrelsens beretning og det aflagte regnskab for 2012 blev godkendt afgeneralforsamlingen. ... [Published GlobeNewswire - Apr 17 2013]

Entities: BAVARIAN NORDIC A/S

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

Bavarian Nordic Receives Contract Valued up to USD 228 Million from the U.S. Government Securing Continued Production...

New order replenishes existing doses in U.S. Strategic National Stockpile, and helps bridge to the next-generation freeze-dried formulation is availableKVISTGAARD, Denmark, Munich, Germany, April 16, 2013Bavarian Nordic A/S (OMX: BAVA) announced today ... [Published BioM - Apr 18 2013]

Entities: BAVARIAN NORDIC A/S, Vaccine, United States Government, Infectious Diseases, Anders Hedegaard

First reported Apr 17 2013 - Updated Apr 18 2013 - 4 reports

Bavarian Nordic A/S ? Report on the Results of the Annual General Meeting, held 17 April 2013

The Board of Directors' Report and Financial Statement for 2012 were adopted at the General Meeting. The Board of Directors' proposal to transfer the Company's 2012 result to next year was also adopted.The General Assembly adopted a resolution to discharge ... [Published Noodls - Apr 18 2013]

Entities: BAVARIAN NORDIC A/S, Anders Gersel Pedersen, Deloitte, Financial Statement

First reported Apr 16 2013 - Updated Apr 17 2013 - 6 reports

US awards new vaccine contract to Bavarian Nordic

The US government has awarded Bavarian Nordic A/S of Denmark a new contract valued at up to $228 million for the continued supply of the smallpox vaccine Imvamune for the nation’s stockpFull text available to subscribers only. Click here for information ... [Published MedNous - Apr 17 2013]

Entities: BAVARIAN NORDIC A/S, Vaccine, Smallpox, New Contract

First reported Apr 08 2013 - Updated Apr 08 2013 - 1 reports

Bavarian Nordic plans interim ana...

What would you like us to do with the funds you've selectedBy BFN NewsMonday 08 April, 2013 at 08:19 AM If a star manager leaves a fund you hold, are you more likely to follow them or stay put? ... [Published TrustNet - Apr 08 2013]

Entities: BAVARIAN NORDIC A/S

First reported Apr 08 2013 - Updated Apr 08 2013 - 1 reports

Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 Trial

- Bavarian Nordic A/S (OMX: BAVA) today announced that the Company plans to conduct an interim analysis of the on-going PROSPECT Phase 3 trial of PROSTVAC® in prostate cancer patients with metastatic disease. The updated statistical analysis plan for ... [Published GlobeNewswire - Apr 08 2013]

Entities: BAVARIAN NORDIC A/S, Phase III, Prostate Cancer, Vaccine, Phase II

Quotes

(live-PR.com) - Global Markets Direct's, "Gram-Positive Bacterial Infections"

Now Available: Gram-Positive Bacterial Infections - Pipeline Review, H1 2013 [Published Live-PR.com - May 05 2013]

Dr. James Breitmeyer, who was recently appointed President of BN Immunotherapeutics, Inc. said, "Enrollment in the PROSPECT study has been my first priority since I joined the company in February. Several enhancements to study conduct have been made to catch upup on enrollment. Specifically, we have refocused our efforts towards high-performing clinical trial sites, an awareness program has been implemented, and we have hired additional internal and external resources to allow for a closer dialogue with the increasing number of clinical trial sites."

Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Ph ... [Published Asian Hospital & Healthcare Management - Apr 29 2013]

Research and Markets has announced the addition of the report to their offering. " provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Scope - A snapshot of the global therapeutic scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. - A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Development - Active Biotech AB - Aduro BioTech - AstraZeneca PLC - Bavarian Nordic A S - Bellicum Pharmaceuticals, Inc. - Bristol-Myers Squibb Company - Eli Lilly and Company - Exelixis Inc. - GTx Inc. - GenSpera Inc. - Genentech Inc. - Johnson & Johnson - Medivation Inc. - Merck & Co Inc. - Merck KGaA - Millennium Pharmaceuticals Inc. - Nerviano Medical Sciences S r.l. - Novartis AG - Oncogenex Pharmaceuticals Inc. - Oncothyreon Inc - Progenics Pharmaceuticals Inc. - Synta Pharmaceuticals Corp. - TRACON Pharmaceuticals, Inc. - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited Drug Profiles - ipilimumab - DI-17-E-6 - PSMA ADC - GTx-758 - enzalutamide - cabozantinib - ganetespib - rilimogene galvacirepvec - PX-866 - BMTP-11 - BPX-101 [AP-1903] - cediranib maleate [prednisone] - buparlisib - custirsen sodium [docetaxel] - TRC-105 - vandetanib [bicalutamide] - enzastaurin hydrochloride [docetaxel] [prednisone] - bortezomib [mitoxantrone hydrochloride] - cixutumumab [mitoxantrone hydrochloride] [prednisone] - OGX-427 [prednisone] - GVAX Prostate Cancer Vaccine - TL-118 - orteronel [prednisone] - mRNA- Transfected Dendritic Cells - RG-7450 - abiraterone acetate [docetaxel] [prednisone] - CFG-920 - Dendritic Cell Vaccination [docetaxel] - Androgen Receptor Antagonists For more information visit CONTACT: Research and Markets, Laura Wood, Senior Manager. press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Sector: Oncology (http://www.researchandmarkets.com/categories.asp?cat_id=122&campaign_id=22mtdx)"

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipe ... [Published Individual.com - Apr 23 2013]

...or atopic dermatitis, including children, pregnant women, and nursing mothers," said Anders Hedegaard, President and CEO of Bavarian Nordic. "This order underscores the long-term relationship that exists between BARDA and Bavarian Nordic. As we work to develop a next-generation freeze-dried formulation of IMVAMUNE® that offers a number of advantages, the current order goes a long way to bridge the gap by replenishing the inventory of the current frozen vaccine formulation. Also, it enables us to move the company forward in the development of further countermeasures to serve the government's needs."

Bavarian Nordic Receives Contract Valued up to USD 228 Million from the U.S. Government Securing ... [Published BioM - Apr 18 2013]

More Content

sort by: Date \| Relevance
Bavarian Nordic A/S Maintains FY 2013 Financial... [Published Reuters - May 16 2013]
New Report Examines Therapeutic Cancer Vaccine ... [Published Pharma-Mag - May 15 2013]
Bavarian Nordic to Host First Quarter 2013 Resu... [Published ACN Newswire - May 08 2013]
Now Available: Gram-Positive Bacterial Infectio... [Published Live-PR.com - May 05 2013]
Bavarian Nordic A/S - Articles of Association [Published Reuters - May 02 2013]
Bavarian Nordic A/S - Vedtægter [Published GlobeNewswire: Advertising News - May 02 2013]
Bavarian Nordic A/S - Articles of Association [Published GlobeNewswire: Advertising News - May 02 2013]
Bavarian Nordic Agrees on Interim Analysis with... [Published Asian Hospital & Healthcare Management - Apr 29 2013]
Ovarian Cancer - Pipeline Review, H1 2013 - New... [Published Live-PR.com - Apr 25 2013]
Bavarian Nordic A/S - Storaktionærmeddelelse [Published GlobeNewswire: Acquisitions News - Apr 24 2013]
Bavarian Nordic A/S - Major Shareholder Announc... [Published GlobeNewswire: Acquisitions News - Apr 24 2013]
Bavarian Nordic A/S - Major Shareholder Announc... [Published Reuters - Apr 24 2013]
Metastatic Hormone Refractory (Castration Resis... [Published Individual.com - Apr 23 2013]
Bavarian Nordic Receives Contract Valued up to ... [Published BioM - Apr 18 2013]
Media Release Interim Report as of March 31, 2013 [Published Noodls - Apr 18 2013]
Bavarian Nordic A/S ? Report on the Results of ... [Published Noodls - Apr 18 2013]
BAVARIAN NORDIC A/S: Report on the Results of ... [Published 4 Traders - Apr 18 2013]
Biotech sector maintains upward trend in first ... [Published Yahoo! Finance - Apr 18 2013]
BB BIOTECH AG: Biotech sector maintains upward ... [Published FinanzNachrichten.de - Apr 18 2013]
BB BIOTECH AG : Biotech sector maintains upward... [Published Investegate - Apr 18 2013]
Biotech sector maintains upward trend in first ... [Published Zecco - Apr 18 2013]
Antiretroviral Therapy Update From the 48th ICA... [Published The AIDS Reader - Apr 18 2013]
Bavarian Nordic A/S - Report on the Results of ... [Published Reuters - Apr 17 2013]
Bavarian Nordic A/S - Report on the Results of ... [Published GlobeNewswire - Apr 17 2013]
Bavarian Nordic A/S - Orientering om forløb af ... [Published GlobeNewswire - Apr 17 2013]
Research and Markets: Respiratory Syncytial Vir... [Published Business Wire - Apr 17 2013]
Respiratory Syncytial Virus (RSV) Infections - ... [Published PredictWallStreet - Apr 17 2013]
US awards new vaccine contract to Bavarian Nordic [Published MedNous - Apr 17 2013]
Bavarian Nordic Receives Contract Valued up to ... [Published Yahoo! Finance - Apr 16 2013]
Bavarian Nordic Receives Contract Valued up to ... [Published Saudi Fransi Capital - Apr 16 2013]

Blogs

sort by: Date \| Relevance
New Report Examines Therapeutic Cancer Vaccine ... [Published Pharma-Mag - May 15 2013] “Therapeutic Cancer Vaccines – Current Status and Future Promise” is the title of a new report by Fran Brown, Senior Advisor at healthcare corporate finance and strategy specialist, Results Healthcare. The report begins by looking at the approval of ...
The Future of Biodefense: Will Public-Private P... [Published I Am Biotech - Dec 10 2012] Ten years ago, in the wake of the 2001 anthrax attacks, the U.S. government set out on a bold path to improve the country’s preparedness for bioterrorism by developing and stockpiling new drugs and vaccines to protect Americans from health emergencies. ...

Press Releases

sort by: Date \| Relevance
Bavarian Nordic A/S - Vedtægter [Published GlobeNewswire: Advertising News - May 02 2013]
Bavarian Nordic A/S - Articles of Association [Published GlobeNewswire: Advertising News - May 02 2013]
Bavarian Nordic A/S - Storaktionærmeddelelse [Published GlobeNewswire: Acquisitions News - Apr 24 2013]
Bavarian Nordic A/S - Major Shareholder Announc... [Published GlobeNewswire: Acquisitions News - Apr 24 2013]
Research and Markets: Respiratory Syncytial Vir... [Published Business Wire - Apr 17 2013]